Please login to the form below

Not currently logged in
Email:
Password:

Loxo

This page shows the latest Loxo news and features for those working in and with pharma, biotech and healthcare.

Roche pays $775m upfront to access Blueprint’s RET programme

Roche pays $775m upfront to access Blueprint’s RET programme

Blueprint’s main rival, Loxo Oncology, also has an oral RET inhibitor – Retevmo (selpercatinib) – in its arsenal that is FDA-approved in RET fusion-positive NSCLC, advanced or metastatic RET-mutant ... Eli Lilly scooped up Loxo in January 2019 for

Latest news

More from news
Approximately 6 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    This is the first US product approval for Loxo Oncology and its marketing partner Bayer, becoming the second company to get FDA backing for a drug that treats cancer based on ... NTRK fusions are rare – Loxo estimates that there are around 2, 500 to 3,

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due for an FDA verdict in November.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    485. Array BioPharma / Loxo Oncology. Multi-year licence and collaboration. Drug candidate (preclinical) discovery of small molecule drugs for oncology targets.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics